Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?

Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Léonce Kouakanou, Christian Peters, Christine E. Brown, Dieter Kabelitz, Leo D. Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immune checkpoint therapy (ICT) CAR (chimeric antigen receptor) T cells vitamin C (ascorbic acid) cancer immunotherapies cancer biology Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/54ab80f3acfe4528b4454f124f0104e0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54ab80f3acfe4528b4454f124f0104e0
record_format	dspace
spelling	oai:doaj.org-article:54ab80f3acfe4528b4454f124f0104e02021-12-01T09:17:59ZVitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?1664-322410.3389/fimmu.2021.765906https://doaj.org/article/54ab80f3acfe4528b4454f124f0104e02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.765906/fullhttps://doaj.org/toc/1664-3224Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo. Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies.Léonce KouakanouChristian PetersChristine E. BrownDieter KabelitzLeo D. WangLeo D. WangFrontiers Media S.A.articleimmune checkpoint therapy (ICT)CAR (chimeric antigen receptor) T cellsvitamin C (ascorbic acid)cancer immunotherapiescancer biologyImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint therapy (ICT) CAR (chimeric antigen receptor) T cells vitamin C (ascorbic acid) cancer immunotherapies cancer biology Immunologic diseases. Allergy RC581-607
spellingShingle	immune checkpoint therapy (ICT) CAR (chimeric antigen receptor) T cells vitamin C (ascorbic acid) cancer immunotherapies cancer biology Immunologic diseases. Allergy RC581-607 Léonce Kouakanou Christian Peters Christine E. Brown Dieter Kabelitz Leo D. Wang Leo D. Wang Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
description	Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo. Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies.
format	article
author	Léonce Kouakanou Christian Peters Christine E. Brown Dieter Kabelitz Leo D. Wang Leo D. Wang
author_facet	Léonce Kouakanou Christian Peters Christine E. Brown Dieter Kabelitz Leo D. Wang Leo D. Wang
author_sort	Léonce Kouakanou
title	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
title_short	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
title_full	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
title_fullStr	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
title_full_unstemmed	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
title_sort	vitamin c, from supplement to treatment: a re-emerging adjunct for cancer immunotherapy?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/54ab80f3acfe4528b4454f124f0104e0
work_keys_str_mv	AT leoncekouakanou vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy AT christianpeters vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy AT christineebrown vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy AT dieterkabelitz vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy AT leodwang vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy AT leodwang vitamincfromsupplementtotreatmentareemergingadjunctforcancerimmunotherapy
_version_	1718405354137583616

Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?

Ejemplares similares